Navigation Links
Researchers identify novel pathway responsible for infection of a common STD pathogen
Date:2/27/2012

Boston Researchers from Boston University School of Medicine (BUSM) have for the first time identified a novel pathway that is necessary for infection to occur with the pathogen Neisseria gonorrhoeae, which is responsible for the second most common infectious disease worldwide, gonorrhea. The study, which was recently published online in the Journal of Bacteriology, may lead to new treatment methods for this sexually transmitted disease.

N. gonorrhoeae is a pathogenic bacterium that readily develops resistance to antibiotics such as sulfanilamides, penicillins, tetracyclines and fluoroquinolones. It has recently been reported that N. gonorrhoeae is becoming resistant to cephalosporins, which are the only treatment option recommended by the Centers for Disease Control and Prevention (CDC). Today, new therapeutic methods other than antibiotics are in great need to treat these infections.

According to the BUSM researchers, understanding the process of how N. gonorrhoeae causes disease in both men and women is essential for the design of new targets to block the infection. "The first step in the disease gonorrhea is the colonization of bacteria on human mucosal surfaces, such as the vaginal and penile mucosa," explained senior author Caroline Genco, PhD, professor of medicine and microbiology and director of research in infectious diseases at BUSM.

In this study, Genco and her colleagues identified a novel pathway that is critical for colonization of this bacterium on host mucosal surface. The key of this pathway is a single protein, designated as Fur, the ferric uptake regulatory protein, which controls the expression of hundreds of N. gonorrhoeae genes by either increasing or decreasing the expression of these genes.

The study found that genes whose expression is increased by Fur may play a critical role in the prevention of disease development by triggering the host immune system to recognize and clear the bacterium.

"These pivotal studies provide new candidates that can be targeted for therapeutic intervention in this common sexually transmitted disease," she added.


'/>"/>
Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. NC State researchers get to root of parasite genome
2. Researchers find animal with ability to survive climate change
3. Researchers find an essential gene for forming ears of corn
4. Researchers note differences between people and animals on calorie restriction
5. Researchers study acoustic communication in deep-sea fish
6. Researchers discover that growing up too fast may mean dying young in honey bees
7. Researchers study how pistachios may improve heart health
8. UI researchers find potentially toxic substance present in Chicago air
9. Researchers develop new self-training gene prediction program for fungi
10. Case Western Reserve University researchers track Chernobyl fallout
11. Childrens National researchers develop novel anti-tumor vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/12/2019)... (PRWEB) , ... November 12, 2019 , ... ... Cross-Channel Spend Optimizer that improves digital advertising performance up to 25% and reduces ... Advertising, Cross-Channel Spend Optimizer uses advanced multi-touch attribution (MTA) to predict best advertising ...
(Date:11/11/2019)... (PRWEB) , ... November 11, 2019 , ... ... (NGS) in microbial identification, played a key role in the award-winning study “Next ... by the Rothman Institute. The molecular diagnostic laboratory processed samples using Next Generation ...
(Date:11/7/2019)... ... ... R3 Stem Cell is now offering its comprehensive Online Stem Cell Training ... during checkout is FIFTYOFF and applies to both the one month access and the ... over 12,000 successful stem cell procedures performed nationwide. A couple years ago, R3 began ...
Breaking Biology News(10 mins):
(Date:11/12/2019)... ... November 12, 2019 , ... ... biopharmaceutical R&D, today announced that Immatics Biotechnologies , a clinical-stage biopharmaceutical ... to streamline their R&D operations related to the discovery and development ...
(Date:11/9/2019)... ... November 08, 2019 , ... ... for use in pathology research, today announced the results of analyses examining ... enrolled in the phase 3 selonsertib studies (STELLAR). Strong correlations were demonstrated ...
(Date:11/5/2019)... ... November 05, 2019 , ... Focal Healthcare , ... for its Fusion Bx 2.0 prostate fusion biopsy solution. By combining information from ... 2.0 will give urologists across Europe the ability to perform targeted transrectal and ...
(Date:11/2/2019)... ... 2019 , ... drug360 graph, a breakthrough knowledge graph product, ... tellic’s expertise in biomedical language processing and machine learning to bear on biomedical ... diseases, variants, phenotypes, and other biomedical entities. Researchers and analysts can use ...
Breaking Biology Technology: